HIVManagement.org

 

Quick Menu / Table of Contents
Introduction Principles Management NRTI Info NNRTI Info
PI Info Fusion Inhibitors Drug Summary Investigational Adherence
Lab Evaluation Resistance Tests PEP Antiretroviral Tables OI Prevention
Vaccinations TB Therapy Hepatitis Therapy OI Diagnosis OI Therapy
Bibliography Links Palliative Therapy

 

lamivudine

Detailed Prescribing Information

 

Epivir  = lamivudine = 3TC
Also a component of
Combivir, Trizivir, & Epzicom
Forms Available 150 mg or 300 mg tablets; liquid 50 mg/5 cc
lamivudine 150 mg combined with zidovudine 300 mg as Combivir
lamivudine 150 mg combined with zidovudine 300 mg and abacavir 300 mg as Trizivir
lamivudine 300 mg combined with abacavir 600 mg as Epzicom
Dosing 150 mg twice a day or 300 mg once a day
Reduce dosing for renal failure
Renal dosing1 Ccr
(cc/min)
Dose
(mg)
> 50 150 twice a day or 300 daily
30-49 150 daily
15-29 150 first dose, then 100 daily
5-14 150 first dose, then 50 daily
< 5 insufficient data
consider 150 first dose, then 25 daily
Hepatic dosing: no dose adjustment is required
Food dependence This medication may be taken with or without food.
Adverse Effects Few if any (hair loss?)
Rare lactic acidosis and hepatic steatosis

Rarely associated with pancreatitis.

Interactions None significant
Suggested lab follow-up  Lipase testing as indicated
Warning Flares of hepatitis B may occur if lamivudine is discontinued suddenly.
Low barrier to one-step mutation.  Use only with other potent agents.

Suggested Usage

Do not use in combination with emtricitabine, Truvada, Epzicom, Combivir, Atripla, or Trizivir due to identical mechanism of action or duplication of lamivudine dosing.
Lamivudine has a very low barrier to resistance.  Always ensure that it is used with other potent and active antiretrovirals.

Complete prescribing information

Epivir prescribing information

 

Links to Antiretroviral Sections (click on anything)
Nucleoside & Nucleotide Reverse Transcriptase Inhibitors (NRTI)
AZT  |  ddC  |  ddI  |  d4T  |  3TC  |  ABC  |  FTC  |  TDF  |  Combivir  |  Trizivir  |  Epzicom  |  Truvada  |  Atripla
Nonnucleoside Reverse Transcriptase Inhibitors (NNRTI)
efavirenz  |  nevirapine  |  delavirdine
Protease Inhibitors (PI)  |  Boosted Protease Inhibitors
saquinavir  indinavir  |  ritonavir  |  nelfinavir  |  amprenavir  |  lopinavir + ritonavir  |  atazanavir  |  fosamprenavir  | tipranavir  |  darunavir
Fusion Inhibitors
enfuvirtide
 
Quick Menu / Table of Contents
Introduction Principles Management NRTI Info NNRTI Info
PI Info Fusion Inhibitors Drug Summary Investigational Adherence
Lab Evaluation Resistance Tests PEP Antiretroviral Tables OI Prevention
Vaccinations TB Therapy Hepatitis Therapy OI Diagnosis OI Therapy
Bibliography Links Palliative Therapy


5.3.2007

 


 

1. Renal dosing information from: Ian R. McNicholl & Rudolph A. Rodriguez, MD, Dosing of Antiretroviral Drugs in Renal Insufficiency and Hemodialysis, May 2004
http://hivinsite.ucsf.edu/InSite?page=md-rr-18